Dual Source Ion Mobility-Mass Spectrometer

双源离子淌度-质谱仪

• 批准号: 10431202
• 负责人: John M Koomen
• 金额: $ 116.76万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10431202
• 关键词: Advanced Malignant Neoplasm; Cancer Center; Charge; Chemicals; Complement; Computer software; Core Facility; Crystallization; Data; Data Analyses; Development; Devices; Electrospray Ionization; Funding; Gases; Immune; Individual; Investments; Label; Lipids; Liquid substance; Mass Spectrum Analysis; Measurement; Molecular; Pathology; Peptides; Phase; Proteins; Proteome; Proteomics; Research; Resolution; Resources; Sampling; Source; Spatial Distribution; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Time; Tissues; Training; United States National Institutes of Health; Vendor; Visualization; biomarker discovery; experimental study; high throughput screening; improved; instrument; instrumentation; ion mobility; ion source; mass spectrometer; mass spectrometric imaging; metabolome; metabolomics; new technology; novel; programs; tandem mass spectrometry; tumor; tumor heterogeneity; tumor metabolism

Project Summary/Abstract: The Bruker timsTOF fleX includes a liquid chromatograph (LC), matrix assisted laser desorption ionization (MALDI-2) and electrospray ionization (ESI) sources, trapped ion mobility spectrometer (tims), and quadrupole- time-of-flight (QTOF) mass spectrometer combined into an instrument that can analyze metabolites, lipids, and proteins with high content or high throughput. Most importantly, the gap between these two experiments can be bridged easily when both are conducted on the same instrument; for example, metabolomics data can be effectively integrated with mass spectrometry imaging. To describe the individual components, the liquid chromatograph provides separation of analytes to increase depth of proteome and metabolome sampling. The two ion sources enable analysis of liquid samples (ESI) or arrays of samples co-crystallized with matrix (MALDI). The trapped ion mobility spectrometer (tims) provides data for collision cross section (CCS) calculations to further define each analyte as well as gas phase enrichment of molecules into packets with similar CCS-to-charge ratios for mass analysis. The QTOF provides mass spectrometry and tandem mass spectrometry with high resolution and accurate mass measurement. Vendor software provides support for data analysis in both metabolomics and proteomics as well as visualization and analysis of mass spectrometry imaging. The addition of this instrument to our Proteomics & Metabolomics Core (P&MC) complements our existing LC-MS resources, provides novel capability for ion mobility-mass spectrometry, replaces a MALDI instrument that was decommissioned last year, and enhances resources available for mass spectrometry imaging. As tumor heterogeneity, the tumor-immune interface, and spatial distribution of analytes in tumors now have increasing importance, existing analytical platforms must be modified to meet these needs and additional investments in instrumentation are needed. The Bruker timsTOF fleX complements existing LC-MS instruments and optimizes the value of investment in new technology by lowering sample input requirements, creating capability for spatial omics of tissues, supporting high throughput screening with MALDI-tims-MS, and ion mobility separation of isomeric lipids, metabolites, and post-translationally modified or chemically labeled peptides. Examples provided by Bruker have been confirmed by demonstration data from our own samples. This device also can be used to improve biomarker discovery and integrate molecular measurements with traditional pathology workflows. The placement in a core facility with highly trained staff and extensive institutional support will maximize both the availability to the user group and their benefit from access to the instrument. Together, these advantages are expected to significantly advance cancer metabolomics and proteomics applications at Moffitt Cancer Center to support existing and planned NIH/NCI-funded research and fuel the development of a Cancer Metabolism Program to develop strategies to target tumor vulnerabilities.

项目概要/摘要： 布鲁克timsTOF fleX包括液相色谱仪（LC）、基质辅助激光解吸电离 （MALDI-2）和电喷雾电离（ESI）源、捕获离子迁移谱仪（）和四极- 飞行时间（QTOF）质谱仪组合成一个仪器，可以分析代谢物，脂质， 高含量或高通量的蛋白质。最重要的是，这两个实验之间的差距可以 当两者都在同一仪器上进行时，可以很容易地桥接;例如，代谢组学数据可以 有效地与质谱成像集成。为了描述各个成分，液体 色谱提供分析物的分离，以增加蛋白质组和代谢物组采样的深度。的 两个离子源能够分析液体样品（ESI）或与基质共结晶的样品阵列 （MALDI）。捕获离子迁移谱仪（CCS）为碰撞截面（CCS）提供数据 计算以进一步限定每种分析物以及将分子气相富集成包， 用于质量分析的类似CCS与电荷比。QTOF提供质谱和串联质谱 高分辨率和精确的质量测量的光谱分析。供应商软件支持 代谢组学和蛋白质组学的数据分析以及质谱的可视化和分析 显像将该仪器添加到我们的蛋白质组学和代谢组学核心（P&MC）， 现有的LC-MS资源，为离子迁移率-质谱法提供了新的能力，取代了MALDI 该仪器去年退役，并增加了质谱分析的可用资源 显像由于肿瘤异质性，肿瘤-免疫界面和肿瘤中分析物的空间分布 现在越来越重要，必须修改现有的分析平台，以满足这些需求， 需要对仪器进行额外投资。布鲁克timsTOF flexX是对现有LC-MS的补充 通过降低样品投入要求， 创建组织空间组学的能力，支持使用MALDI-MS的高通量筛选，以及 异构脂质、代谢物和后修饰或化学标记的离子迁移率分离 缩氨酸布鲁克提供的示例已被我们自己的样品的演示数据所证实。 该装置还可用于改善生物标志物发现并将分子测量与生物标志物的生物标志物结合。 传统的病理学工作流程。安置在一个核心设施与训练有素的工作人员和广泛的 机构支助将最大限度地向用户群体提供服务， 仪器总之，这些优势有望显著推进癌症代谢组学， Moffitt癌症中心的蛋白质组学应用，以支持现有和计划中的NIH/NCI资助的研究， 推动癌症代谢计划的发展，以制定针对肿瘤脆弱性的战略。